Low dose aspirin for MS-related fatigue: Results of a pilot, double-blind, randomized trial

Fatigue is one of the most common and disabling symptoms in Multiple Sclerosis (MS). We aimed to evaluate the effects of low dose Aspirin (80 mg) in primary fatigue in MS patients. This is a single-center, randomized, double-blind and parallel trial with 1:1 ratio allocation of two treatment groups of low dose Aspirin (80 mg) and placebo in outpatients with MS-related fatigue. Treatment strategy was applied for 8 weeks in definitely diagnosed MS patients. Patients were assessed by means of modified fatigue impact scale (MFIS) and fatigue severity scale (FSS). Patients were also evaluated for side effects and tolerability of the drug. One hundred and twenty patients with MS were randomized. Among them, 100 patients entered final analysis. No significant effect in FSS and MFIS was found regarding intervention arms using ANOVA for repeated measure. Independent sample T-test, examining absolute changes for FSS score (Endpoint − Baseline), reveals Aspirin supremacy against placebo which was statistically significant. Aspirin in 80 mg did not convey a significant difference in either group. However the absolute changes among the two treatment arms appeared meaningful in FSS but not in MFIS. Therefore, the probability of Aspirin effectiveness exists, however it is not provable in repeated measure analysis as a result of substantial drop out and relatively short treatment period.